From: Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia
Outcome
No palivizumab
Palivizumab
Total discounted direct costs
$ 4,056,239
$ 2,534,193
RSV-related hospitalizations
349
76
∆ Costs (palivizumab– no palivizumab)
- $ 1,522,046
∆ QALYs (palivizumab– no palivizumab)
125